a laptop screen with a webpage of the IT Army of Ukraine group of volunteer hackers. The IT Army of Ukraine first set up in the wake of Russia's devastating attack, and has since hugely grown in ...
An AI assistant for high-entropy alloy (HEA) electrocatalysis named ChatHEA provided a helping hand not just to extract data ...
India’s white-collar professionals have spent a decade optimising for one of two outcomes: deeper as a specialist, or wider ...
Educating used to be about explaining concepts – now it’s about designing experiences to help the brain develop understanding. Find advice to tweak your teaching here ...
Time Walker on MSN
A remarkable Chinese office complex built around flowing architectural forms and space
This contemporary office complex highlights a distinctive architectural style that moves beyond traditional rectangular ...
Modern business intelligence demands speed, and utilizing AI tools for Excel is the ultimate way to hyper-charge your data workflows this year.
Following the New York Knicks' 105-104 win over the San Antonio Spurs in Game 2 of the NBA Finals on Friday night, ticket prices for Games 3 and 4 at Madison Square Garden skyrocketed. The possibility ...
CNET editor Gael Fashingbauer Cooper, a journalist and pop-culture junkie, is co-author of "Whatever Happened to Pudding Pops? The Lost Toys, Tastes and Trends of the '70s and '80s," as well as "The ...
Between May 6 and 7, four security research teams published findings about Anthropic’s Claude that most outlets covered as three separate stories. One involved a water utility in Mexico, another ...
Open-source reinforced concrete design toolkit for IS 456:2000. Use it as a Python package, a CLI, a FastAPI backend, or a React app.
Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results